Inside Vertex Pharmaceuticals’ Clinical Pipeline
In March 2017, Vertex Pharmaceuticals (VRTX) announced promising results from two phase-3 clinical trials, Evolve and Expand.
Vertex (VRTX) has planned to submit a new drug application to the FDA in 3Q17 for a Tezacaftor-Ivacaftor combination treatment for cystic fibrosis.
In 2016, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $979 million, reflecting ~180% YoY (year-over-year) growth.
Mylan’s Key Developments and Big Plans: What You Should Know
The recent developments reported by Mylan (MYL) include commercial developments and product developments. Let’s take a closer look.
Mylan (MYL) reported an increase of 17% in revenues at ~$2.2 billion in 1Q16 from $1.9 billion in 1Q15.
The specialty segment reported an increase of 17% in revenues at $247.9 million in 1Q16 versus $211.1 million in 1Q15.
Medicare Business Expected to Drive WellCare Health Plans’ Margin Growth
In 1Q17, WellCare Health Plans’ (WCG) Medicare Health Plans business reported revenues close to $1.1 billion, which represents year-over-year growth of ~12.4%.
WellCare Health Plans has updated its earnings per share guidance from the previously estimated range of $6.00–$6.25 to the new range of $6.55–$6.80.
In 1Q17, WellCare Health Plans (WCG) reported revenues of ~$3.9 billion, which totals year-over-year growth of around 11.7%.
Molina Healthcare: Why Molina’s revenues have been growing fast
Molina Healthcare, Inc. (MOH): Revenue growth In general, Medicaid health plans grow revenue by increasing their membership or generating higher rates from state governments. The latter portion is often left up…
Investor day could provide a positive update to long-term growth MOH has been under pressure of late, without much reason. After beating 2Q consensus EPS estimates, even after including roughly…
Molina Healthcare, Inc. (MOH): Market overview Medicaid is a rapidly growing segment within healthcare, which should directly benefit MOH. In addition to typical market growth of mid-single digits, there are several…
Yellen’s Caution Led Battered Healthcare Up 1.2% on March 29
With the Fed stressing caution, investor sentiment turned toward the utilities and healthcare sectors, which rose 1.5% and 1.2%, respectively, on March 29.
Henry Schein reported 3Q15 net sales of $2,685.8 million, a rise of 2.4% compared to the net sales of $2,623.7 million in fiscal 3Q14.
The Health Care Select Sector SPDR ETF (XLV) has by and large been an outperformer in 2015. It has returned 5.1% on a YTD (year-to-date) basis.
How Could Trump’s Presidency Affect Hospitals and Insurance?
Donald Trump is definitely not in favor of the Affordable Care Act, known as Obamacare. As he wants to repeal the act completely and replace it with another policy, the hospital…
While the recent trade cases have buoyed the US steel industry, Europe is still weak. A major recovery in U.S. Steel’s Europe earnings looks elusive in the near-term.
Wall Street analysts have projected that Universal Health Services’ net profit margin will increase marginally from 7.5% in 2015 to 7.6% in 2016.
Baxter Is Focusing on Inorganic Growth Opportunities in 2017
Baxter (BAX) has entered into a strategic partnership with ScinoPharm for the development and manufacturing of five generic oncology injectable therapies.
Baxter International has been focused on leveraging both organic and inorganic growth opportunities for its IPS business.
In 1Q17, Baxter’s (BAX) renal segment reported revenues close to $896.0 million, which is an operational growth of around 2.0% YoY.
Pfizer’s Geographical Performance in 1Q17
The Innovative Health segment reported a 9.0% rise in 1Q17 revenues compared to 1Q16 revenues from sales in the US markets.
Pfizer’s gross margin for 1Q17 was 81.0%, a 0.70% rise compared to 80.3% in 1Q16.
Pfizer (PFE) reported a 2.0% fall in 1Q17 revenues to ~$12.8 billion, with a 1.0% operational fall in revenues and a 1.0% negative impact of foreign exchange.